Mylan announced it has received final approval from the FDA for its Abbreviated New Drug Application (ANDA) for Telmisartan Tablets, the generic version of Boehringer Ingelheim’s Micardis.

Telmisartan is an angiotensin II receptor blocker indicated for the treatment of hypertension and cardiovascular risk reduction in patients ≥55 years of age who are unable to take ACE inhibitors. Telmisartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor in many tissues, such as vascular smooth muscle and the adrenal gland.

RELATED: Hypertension Treatments: ARBs

Telmisartan Tablets are available in 20mg, 40mg, and 80mg strengths.

For more information call (800) RX-MYLAN or visit